by Karl Denninger
Market-Ticker.org
[…] For those who can’t do basic math I’ll do it for you: Group I was people with mild and moderate symptoms. Group III was those with severe symptoms (and presumed hospitalization given the listed criteria.)
Groups II and IV were on the same criteria but with their standard of care, including HCQ.
May I point out the important point here — in the mildly-ill presenting people this drug dropped the mortality to ZERO and almost-completely (99% of the time) cut off progression to more-serious disease.
In the severely ill people, who had already gotten in a lot of medical trouble with the virus, it dropped mortality by 90%.